After years working with CHCs, John Torontow, M.D., M.Ph., sees value-based care as more than a payment strategy. He argues it is an opportunity to make the health centers’ often-invisible work measurable, recognized and financially sustainable.
Why the flood of consumer wellness devices demands clear boundaries between lifestyle improvement and clinical diagnostics The post The Imperative of Distinguishing Medical-Grade Devices from Wellness Tech appeared first on MedCity News.
As adoption accelerates, organizations must ensure that the use of AI strengthens and not weakens accountability and patient safety. The post AI in Pharmacovigilance: Why Governance Will Define Success appeared first on MedCity News.
Ohio health system, acquired by General Catalyst, reveals list of vendor partners, including Aidoc, Clarium, Commure, Fabric, and Transparent
Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill. For six months in 2022, Manski received monthly infusions of nivolumab to fight advanced melanoma. The drug ruined his thyroid gland, he…
Nurse Crystal Dhooghe is used to dealing with blood and broken bones in the emergency room. But she didn’t expect to witness so much violence against her own colleagues. “I’ve seen nurses get shoved, pushed, scratched. The biggest one is bitten,” said Dhooghe, who works at Henry Ford Genesys Hospital in Grand Blanc, Michigan. The…
By EMANUEL SARKEES Most people have never heard of prior authorization until it personally stops them from getting care they actually need. The way it usually goes is pretty straightforward: a doctor sees a patient, figures out what is wrong, decides on a treatment, and writes the order. Then everything stops. Before anything can actually…
Happy Health’s $75 million round was from ARCH Venture Partners and OpenLoop. The post Happy Health Snags $75M to Support Home-Based Care appeared first on MedCity News.
Merck and Moderna said intismeran autogene, an mRNA cancer vaccine that prompts an immune response to proteins expressed by a patient’s tumors, met the main goal of a pivotal test in melanoma. It’s the most advanced trial in a 50/50 partnership evaluating the personalized cancer treatment in a wide range of tumor types. The post…
The partnership establishes the first M.D.-granting medical school branch on Tribal land, emphasizing community-based training